Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at 120 sites worldwide with patient enrollment expected as early as the beginning of 2023 --
-- Interim results expected approximately one year after patient enrollment begins --
-- CAL02 is being developed as an add-on to the clinically indicated antibiotic treatment and potentially offers unique therapeutic benefits to critically ill patients, including immediate decrease in inflammatory biomarkers, shorter duration of critical care management such as mechanical ventilation, and ultimately a reduced mortality risk --
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.